Literature DB >> 3362362

Alzheimer's disease and Parkinson's disease: comparison of speech and language alterations.

J L Cummings1, A Darkins, M Mendez, M A Hill, D F Benson.   

Abstract

Speech and language alterations were assessed in 51 patients with Parkinson's disease (PD) and 10 patients with dementia of the Alzheimer type (DAT). Thirty-five of the PD patients had no evidence of intellectual impairment on a conventional mental status questionnaire and 16 of the PD patients had dementia syndromes of comparable severity to the DAT patients. DAT produced significantly greater language disturbances, including anomia, decreased information content of spontaneous speech, and diminished word list generation. PD patients had significantly decreased phrase length, impaired speech melody, dysarthria, and agraphia. The results suggest that the dementia of PD is distinguishable from that of DAT:PD patients have prominent motor speech abnormalities, whereas DAT patients exhibit more profound language alterations.

Entities:  

Mesh:

Year:  1988        PMID: 3362362     DOI: 10.1212/wnl.38.5.680

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  19 in total

1.  Apathy in Parkinson's disease.

Authors:  G C Pluck; R G Brown
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-12       Impact factor: 10.154

Review 2.  Mild cognitive impairment in Parkinson's disease.

Authors:  J G Goldman; I Litvan
Journal:  Minerva Med       Date:  2011-12       Impact factor: 4.806

3.  The organization and anatomy of narrative comprehension and expression in Lewy body spectrum disorders.

Authors:  Sharon Ash; Sharon X Xie; Rachel Goldmann Gross; Michael Dreyfuss; Ashley Boller; Emily Camp; Brianna Morgan; Jessica O'Shea; Murray Grossman
Journal:  Neuropsychology       Date:  2012-02-06       Impact factor: 3.295

4.  Improved cognition while cycling in Parkinson's disease patients and healthy adults.

Authors:  Audrey A Hazamy; Lori J P Altmann; Elizabeth Stegemöller; Dawn Bowers; Hyo Keun Lee; Jonathan Wilson; Michael S Okun; Chris J Hass
Journal:  Brain Cogn       Date:  2017-01-11       Impact factor: 2.310

Review 5.  Neuropsychological aspects of Parkinson's disease.

Authors:  S A Raskin; J C Borod; J Tweedy
Journal:  Neuropsychol Rev       Date:  1990-09       Impact factor: 7.444

6.  Longitudinal decline in speech production in Parkinson's disease spectrum disorders.

Authors:  Sharon Ash; Charles Jester; Collin York; Olga L Kofman; Rachel Langey; Amy Halpin; Kim Firn; Sophia Dominguez Perez; Lama Chahine; Meredith Spindler; Nabila Dahodwala; David J Irwin; Corey McMillan; Daniel Weintraub; Murray Grossman
Journal:  Brain Lang       Date:  2017-05-17       Impact factor: 2.381

7.  Neuropsychologic assessment in collaborative Parkinson's disease research: a proposal from the National Institute of Neurological Disorders and Stroke Morris K. Udall Centers of Excellence for Parkinson's Disease Research at the University of Pennsylvania and the University of Washington.

Authors:  G Stennis Watson; Brenna A Cholerton; Rachel G Gross; Daniel Weintraub; Cyrus P Zabetian; John Q Trojanowski; Thomas J Montine; Andrew Siderowf; James B Leverenz
Journal:  Alzheimers Dement       Date:  2012-11-16       Impact factor: 21.566

8.  Neuropsychological and psychiatric differences between Alzheimer's disease and Parkinson's disease with dementia.

Authors:  S E Starkstein; L Sabe; G Petracca; E Chemerinski; G Kuzis; M Merello; R Leiguarda
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-10       Impact factor: 10.154

9.  Linguistic complexity, speech production, and comprehension in Parkinson's disease: behavioral and physiological indices.

Authors:  Bridget Walsh; Anne Smith
Journal:  J Speech Lang Hear Res       Date:  2010-11-08       Impact factor: 2.297

10.  Improvement of spontaneous speech in early stage Alzheimer's with rivastigmine.

Authors:  E G Visch Brink; W Van Rhee Temme; T Rietveld; J W M Krulder; F Van Harskamp; T J M Van der Cammen
Journal:  J Nutr Health Aging       Date:  2009-01       Impact factor: 4.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.